a multiplex assay to measure rna transcripts of prostate cancer in urine一种多元分析方法来衡量rna转录的前列腺癌尿液.pdfVIP

A Multiplex Assay to Measure RNA Transcripts of Prostate Cancer in Urine 1,2 1,2 1,2 1 3 1,2 Sue-Ing Quek *, Melissa E. Ho , Michelle A. Loprieno , William J. Ellis , Nathan Elliott , Alvin Y. Liu 1 Department of Urology, University of Washington, Seattle, Washington, United States of America, 2 Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, United States of America, 3 nanoString Technologies, Seattle, Washington, United States of America Abstract The serum prostate-specific antigen (PSA) test has a high false positive rate. As a single marker, PSA provides limited diagnostic information. A multi-marker test capable of detecting not only tumors but also the potentially lethal ones provides an unmet clinical need. Using the nanoString nCounter gene expression system, a 20-gene multiplex test was developed based on digital gene counting of RNA transcripts in urine as a means to detect prostate cancer. In this test, voided urine is centrifuged to pellet cells and the purified RNA is amplified for hybridization to preselected probesets. Amplification of test cell line RNA appeared not to introduce significant bias, and the counts matched well with gene abundance levels as measured by DNA microarrays. For data analysis, the individual counts were compared to that of b2 microglobulin, a housekeeping gene. Urine samples of 5 pre-operative cases and 2 non-cancer were analyzed. Pathology information was then retrieved. Signals for a majority of the genes were low for non-cancer and low Gleason scores, and 6/6 known prostate cancer markers were positive in the cases. One case of Gleason 4+